ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 928,67
-0,70%
Dow Jones
38 077,79
0,46%
DAX
17 919,07
-0,02%
Brent Oil
83,59
0,06%
Bitcoin
58 860,06
1,07%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Merrimack Pharmaceuticals Inc (MACK)

  7. Merrimack Pharmaceuticals Inc (MACK) Actualités

MACK Merrimack Pharmaceuticals Inc

15,01
0,03 (0,20%)
Dernière mise à jour : 16:18:47
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Merrimack Pharmaceuticals Inc MACK NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,03 0,20% 15,01 16:18:47
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
15,00 14,9608 15,01 14,98
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202423:15BWMerrimack Pharmaceuticals Announces Notification of Plan to..
27/3/202421:30BWMerrimack Receives $225 Million Milestone Payment from Ipsen
07/3/202422:42EDGAR2Form 425 - Prospectuses and communications, business..
07/3/202422:39EDGAR2Form 8-K - Current report
07/3/202422:30BWMerrimack Reports Full Year 2023 Financial Results
07/3/202422:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202418:29EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/3/202422:44EDGAR2Form PRE 14A - Other preliminary proxy statements
14/2/202422:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202422:26EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/2/202422:22EDGAR2Form 8-K - Current report
13/2/202422:18BWMerrimack Reports Ipsen Announcement of Approval By The US..
25/1/202422:05EDGAR2Form SC 13D/A - General statement of acquisition of..
28/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:05EDGAR2Form SC 13D/A - General statement of acquisition of..
11/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202300:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:30BWMerrimack Reports Third Quarter 2023 Financial Results
14/8/202322:05EDGAR2Form SC 13D/A - General statement of acquisition of..
09/8/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202322:36EDGAR2Form 8-K - Current report
03/8/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:30BWMerrimack Reports Second Quarter 2023 Financial Results
04/5/202323:00BW Merrimack Reports First Quarter 2023 Financial Results

Dernières Valeurs Consultées

NASDAQ
MACK
Merrimack Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés